Jack Mourad, MD
Rheumatology · Cranston, RINPI 1912972050
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 206 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 20.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,339 and has fallen 55.4% since, to $597 in 2025.
Across 206 payments — averaging $21.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$920
- Mallinckrodt Hospital Products Inc.$672
- ANI Pharmaceuticals, Inc.$376
- Amgen$354
- UCB, Inc.$297
- Pfizer$280
- plus $2K from 16 others
What the payments were for
- Consulting fees$401%
- Food & beverage$4,42299%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 42 | $920 |
| Mallinckrodt Hospital Products Inc. | 23 | $672 |
| ANI Pharmaceuticals, Inc. | 21 | $376 |
| Amgen(2 entities) | 17 | $354 |
| UCB, Inc. | 12 | $297 |
| Pfizer | 13 | $280 |
| Collegium Pharmaceutical, Inc. | 12 | $223 |
| GSK | 9 | $221 |
| Biodelivery Sciences International, Inc. | 11 | $220 |
| AstraZeneca | 11 | $191 |
| Lilly USA, LLC | 6 | $119 |
| E.r. Squibb & Sons, L.L.C. | 5 | $99 |
| Regeneron Healthcare Solutions, Inc. | 4 | $92 |
| MDD US Operations, LLC | 4 | $85 |
| Johnson & Johnson | 3 | $79 |
| Teva Pharmaceuticals USA, Inc. | 4 | $64 |
| Mallinckrodt Enterprises LLC | 3 | $54 |
| Novo Nordisk | 2 | $33 |
| Exact Sciences | 1 | $23 |
| Medexus Pharma, Inc. | 1 | $21 |
| Kaleo, Inc. | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,462 in reported general payments places this provider in the 70th percentile of 22 rheumatology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 20 | $14,406 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $11,150 |
| OzempicSemaglutide | 11 | $10,423 |
| Xtampza ErOxycodone Myristate | 12 | $7,698 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 15 | $5,427 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 227 | $5,053 |
| Oxycodone Hcl | 92 | $2,673 |
| Atorvastatin Calcium | 120 | $1,586 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 34 | $1,507 |
| Bisoprolol-HydrochlorothiazideBisoprolol/Hydrochlorothiazide | 42 | $1,280 |
| Tramadol Hcl ErTramadol Hcl | 17 | $1,243 |
| Etodolac | 29 | $1,130 |
| Gabapentin | 121 | $1,100 |
| Morphine Sulfate ErMorphine Sulfate | 38 | $1,033 |
| Ventolin HfaAlbuterol Sulfate | 18 | $974 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $33 | $10,42311 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $223 | $7,69812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 22 rheumatology providers in Rhode Island.
Other rheumatology in Cranston
- Deepan DalalCranston$122K
- Matthew WhiteCranston$306
- Edward ReardonWarwick$403K
- Jay ToderJohnston$139K
- Anthony ReginatoE. Providence$109K
- David KadmonLincoln$13K
- Christopher D ArcyWesterly$7K
- Vinit Joseph GilvazPawtucket$4K
- Wendy SilversmithWesterly$3K
- Edward LallyE. Providence$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.